A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes-Reference-Cited by-同舟云学术

A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose—Possible Predictors of Cardiac Outcomes

Published:2020-08-12 Issue: Volume:11 Page:
ISSN:1664-2295
Container-title:Frontiers in Neurology
language:
Short-container-title:Front. Neurol.

Author:

Limmroth Volker,Ziemssen Tjalf,Kleiter Ingo,Wagner Bert,Schmidt Stephan,Lassek Christoph,Baier-Ebert Monika,Wendt Guillaume,Dechend Ralf,Haverkamp Wilhelm

Publisher

Frontiers Media SA

Subject

Clinical Neurology,Neurology

Reference36 articles.

1. The immune modulator FTY720 targets sphingosine 1-phosphate receptors;Brinkmann;J Biol Chem.,2002

2. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial;Calabresi;Lancet Neurol,2014

3. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis;Cohen;N Engl J Med,2010

4. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis;Kappos;N Engl J Med,2010

5. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis;Thomas;Expert Opin. Pharmacother,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 1-Phosphate receptor agonists: A promising therapeutic avenue for ischemia-reperfusion injury management;International Immunopharmacology;2024-04

2. Index of cardiac-electrophysiological balance in relapsing–remitting multiple sclerosis patients treated with fingolimod;Multiple Sclerosis and Related Disorders;2023-08

3. Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more;Expert Opinion on Drug Metabolism & Toxicology;2022-10-03

4. The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary;PLOS ONE;2022-04-22

5. Stroke risk in multiple sclerosis: a critical appraisal of the literature;International Journal of Neuroscience;2022-04-03